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The myeloid-specific transcription factor, CCAAT/enhancer-binding protein ε (C/EBPε) is a critical mediator 
of myelopoiesis. Mutation of this gene is responsible for neutrophil-specific granule deficiency in humans, 
a condition that confers susceptibility to Staphylococcus aureus infection. We found that C/EBPε-deficient 
mice are severely affected by infection with S. aureus, and C/EBPε deficiency in neutrophils contributes to the 
infectious phenotype. Conversely, exposure to the epigenetic modulator nicotinamide (vitamin B3) increased 
expression of C/EBPε in WT myeloid cells. Further, nicotinamide increased the activity of C/EBPε and select 
downstream antimicrobial targets, particularly in neutrophils. In a systemic murine infection model as well as 
in murine and human peripheral blood, nicotinamide enhanced killing of S. aureus by up to 1,000 fold but had 
no effect when administered to either C/EBPε-deficient mice or mice depleted of neutrophils. Nicotinamide 
was efficacious in both prophylactic and therapeutic settings. Our findings suggest that C/EBPε is an impor-
tant target to boost killing of bacteria by the innate immune system.
Introduction
Staphylococcus aureus in community and health care settings com-
monly causes serious and potentially life-threatening infections 
(1–3). Widespread use of antibiotics is responsible for the emer-
gence and rapid spread of resistant pathogens, including methicil-
lin-resistant S. aureus (MRSA) (3), and highlights a pressing need 
for development of novel antimicrobial therapies.
Increasingly, novel therapeutics are identified by studying host 
and bacterial factors that play important roles in the immu-
nopathology of infection. For example, the golden pigment of   
S. aureus is an important virulence factor that shields the patho-
gen from host oxidative killing, and we have previously shown 
that blocking the biosynthesis of this pigment could be a strat-
egy for treatment of S. aureus infection (4). Conversely, among 
human genetic conditions that alter susceptibility to S. aureus 
infection is neutrophil-specific granule deficiency (SGD), a rare 
hematologic disorder characterized by a significantly defective 
immunity (5–8). Patients with SGD present with functional 
defects in neutrophils, as well as monocytes/macrophages, 
and suffer from recurrent life-threatening bacterial infections, 
including S. aureus, Pseudomonas aeruginosa, and Klebsiella pneu-
moniae. Therefore, understanding the defective host immune 
mechanisms conferring susceptibility to S. aureus could lead to 
identification of immune modulatory strategies (9).
Recently, we and others have established the essential role of the 
myeloid-specific transcription factor CCAAT/enhancer-binding 
protein ε (C/EBPε) in the terminal differentiation as well as the 
functional maturation of neutrophils and monocytes/macro-
phages (10–17). Neutrophils from C/EBPε-deficient mice (Cebpe–/– 
mice) display aberrant phagocytosis, respiratory burst, and bacte-
ricidal activities. This phenotype is similar to that of neutrophils 
from individuals with SGD, which led to the discovery of germline 
loss-of-function mutations involving CEBPE in individuals suf-
fering from this disease (11–15, 18, 19). Importantly, in the pres-
ence of all other C/EBP family members, Cebpe–/– neutrophils lack 
expression of all secondary (specific) granule proteins, including 
important antimicrobials, such as lactoferrin (LTF), cathelicidin 
antimicrobial peptide (CAMP), neutrophil gelatinase (NGAL), 
and neutrophil collagenase. In particular, LTF and CAMP have 
been shown to exhibit anti–S. aureus activity (20–22). In addi-
tion, murine and human monocytes/macrophages with impaired 
expression of C/EBPε display signs of immaturity, impaired 
phagocytosis, and altered myelomonocytic-specific gene expres-
sion (8, 13, 16, 17).
Genome-wide expression analyses revealed a substantial role for 
histone deacetylases (HDACs) in the regulation of host defense 
genes, including complement factors, cytokines, chemokines, and 
transcriptional regulators (23–27). Also, the activity of the highly 
conserved family member C/EBPβ is regulated in part by its acety-
lation and deacetylation (28). Therefore, modification of acetyla-
tion could be important for the regulation of the transcription 
factor C/EBPε and its downstream antimicrobial targets. HDAC 
inhibitors are essential epigenetic regulators of transcription that 
modify acetylation of histones and nonhistone proteins (23–27). 
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These inhibitors can block the activity of certain HDACs and 
induce histone acetylation, leading to the relaxation of chromatin 
structure with enhanced accessibility of transcriptional machinery 
to DNA and increased gene transcription (23–25). HDAC inhibi-
tors may also induce protein acetylation of transcription factors, 
resulting in changes in their transcriptional activity and of down-
stream target genes (26, 27). Nicotinamide (NAM), also referred to 
as vitamin B3, is the amide of nicotinic acid and is well known to 
act as a competitive inhibitor of class III HDACs (29–31).
The role of NAM as a modulator of inflammation has been wide-
ly reported. For example, NAM is prescribed topically for treat-
ment of a number of inflammatory skin conditions, including 
acne vulgaris and atopic dermatitis (32). In experimental murine 
models of Gram-positive and Gram-negative sepsis, NAM has been 
shown to improve survival (33, 34). The mechanism contributing 
to immune modulation is not well-defined, but NAM has also been 
shown to suppress secretion of a number of cytokines and chemo-
kines, including IL-1β, TNF-α, IL-6, and iNOS (35, 36). Cellular 
targets of NAM include protein kinase B, forkhead transcription 
factors, poly(ADP-ribose) polymerase, and cysteine proteases (37). 
Suppression of the nuclear enzyme poly(ADP-ribose) polymerase 
is thought to be potentially important (38, 39), as it contributes to 
tissue injury by depletion of NAD+ and by upregulation of inflam-
matory cytokines and chemokines (40, 41). More recently, NAM 
has been shown to induce granulocytosis in human subjects by 
activation of C/EBPα and G-CSF (42).
Interestingly, despite its implication in a number of host 
responses, the role of NAM as an antimicrobial agent is limited. 
NAM has been shown to be effective in amelioration of Mycobac-
terium tuberculosis disease in human subjects (43). More recently, 
Wurtele and colleagues reported that modulation of the yeast 
histone H3 Lys56 acetylation by NAM sensitized Candida albicans 
to genotoxic and antifungal agents (44).
Though Cebpe–/– mice appear more susceptible to spontaneous 
bacterial infection during their life span (12), in vivo challenge exper-
iments with a bacterial pathogen have not been conducted in the   
C/EBPε-deficient background. In this study, we investigated the criti-
cal role of C/EBPε in the innate immune response against S. aureus. 
We showed that, in the absence of functional C/EBPε, mice were 
severely impaired in their ability to clear S. aureus infection. Neutro-
phils from Cebpe–/– mice were unable to kill S. aureus and contributed 
to the pathophysiology of infection. Because C/EBPε appeared essen-
tial for defense against S. aureus, we hypothesized that a pharmaco-
logic agent that enhanced expression of C/EBPε above physiologic 
level might lead to therapeutic killing of S. aureus. In this study, we 
showed that NAM could increase C/EBPε activity and that this in 
turn led to effective immune-mediated clearance of S. aureus.
Results
Impaired response of Cebpe–/– mice to S. aureus infection. Humans and 
mice without functional C/EBPε have significant neutrophil and 
monocyte/macrophage defects, comparable to those of individu-
als with SGD (11–19). To determine the critical role of C/EBPε in 
S. aureus infection, we challenged WT and Cebpe–/– mice with dif-
ferent doses of S. aureus s.c. Compared with WT mice, Cebpe–/– mice 
exhibited dramatic weight loss, significantly larger skin lesion size, 
and more CFUs in the lesions (Figure 1, A–C, and Supplemental 
Figure 1). Additionally, s.c. infection of Cebpe—/— mice was associ-
ated with increased systemic spread of bacteria to the spleens and 
kidneys on day 6 after infection (p.i.; Figure 1C).
Histopathological evaluation with H&E revealed a significantly 
larger number of neutrophils and macrophages in the skin lesions 
of Cebpe–/– mice 24 hours p.i. compared with that in WT mice (Fig-
ure 1D and Supplemental Figure 2; supplemental material avail-
able online with this article; doi:10.1172/JCI62070DS1), which 
was accompanied by high levels of the chemokines CXCL1 (also 
known as KC) and CXCL2 (also known as MIP2) (Figure 1E). These 
data suggest that enhanced accumulation of phagocytic cells at 
the infection site in Cebpe–/– mice failed to control S. aureus infec-
tion and point to the severe defects in the antimicrobial machinery 
in Cebpe–/– phagocytic cells.
To formally assess the ability of Cebpe–/– phagocytic cells to kill 
S. aureus, we used a well-described phagocytic survival assay, in 
which peripheral blood from WT and Cebpe–/– mice was infected 
with S. aureus ex vivo. The assay is commonly used as an approxi-
mate measure of neutrophil killing function. As anticipated, 
bacterial clearance was significantly decreased in the blood of 
the Cebpe–/– mice compared with that of WT mice (Figure 1F and 
Supplemental Figure 3). By comparison, overall bacterial clear-
ance by Cebpe–/– bone marrow–derived macrophages (BMDMs) 
was not significantly different compared with clearance by WT 
macrophages (Figure 1G).
Neutrophils are a critical component of the host immune 
response against S. aureus. To determine the contribution of 
Cebpe–/– neutrophils toward infection in vivo, we performed infec-
tion experiments in WT and Cebpe–/– mice depleted of neutrophils. 
Depletion was achieved by daily injection of mice with a murine 
anti–polymorphonuclear neutrophil (anti-PMN) antibody, start-
ing 24 hours prior to s.c. infection with S. aureus. Administration 
of anti-PMN antibody had no depleting effect on the CD11b-pos-
itive, Ly6G-negative population (monocytes/macrophages), based 
on analysis of splenocytes by flow cytometry (data not shown). As 
expected, in the absence of neutrophils, WT mice showed more 
CFUs at the site of infection (Figure 1H). By contrast, Cebpe–/– mice 
depleted of neutrophils showed significantly fewer CFUs within 
the lesion compared with Cebpe–/– mice with neutrophils (Figure 
1H), suggesting that C/EBPε deficiency in neutrophils is a major 
contributor to the severity of infection in the knockout mice. We 
corroborated this finding using a gentamicin protection assay 
(intracellular survival assay) performed on WT and Cebpe–/– whole 
blood. We showed that S. aureus was readily cleared from WT blood 
but persisted and grew within cellular elements of Cebpe–/– blood 
(Figure 1I, left). In murine infection, H&E staining of infected skin 
showed Cebpe–/– neutrophils full of intracellular S. aureus. By con-
trast, only a few intracellular bacteria were found at the lesion site 
of WT mice (Figure 1I, right). Taken together, these data suggest 
that neutrophils from Cebpe–/– mice do not provide an antimicro-
bial benefit to the host.
NAM augments killing of S. aureus by a C/EBPε-dependent mechanism. 
Because C/EBPε plays a critical role in the host immune response 
against S. aureus infection, we hypothesized that increased expres-
sion of C/EBPε could enhance immune killing of bacteria. As 
proof of principal, we induced overexpression of C/EBPε in a dif-
ferentiated myeloid cell line (45, 46). U937 cells were stably trans-
fected with a zinc-inducible C/EBPε expression vector (pMTε) 
and differentiated using phorbol 12-myristate 13-acetate (PMA). 
Interestingly, the differentiated U937 cells with forced expression 
of C/EBPε killed up to 30-fold more S. aureus compared with vec-
tor control (Figure 2). Zinc alone had no effect on the viability and 
growth of S. aureus (data not shown).research article
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Based on the above findings, we next asked whether a pharma-
cologic agent could induce overexpression of C/EBPε in myeloid 
cells and thereby promote more effective immune-mediated kill-
ing of S. aureus. Skokowa and colleagues recently demonstrated 
that NAM could modify and enhance expression of C/EBPα and 
C/EBPβ (42). Therefore, in this study, we tested whether NAM, as 
a well-established HDAC inhibitor, could also modulate the activ-
ity of C/EBPε.
Peripheral blood drawn from 12 healthy human volunteers was 
pretreated ex vivo with either NAM (1 mM or 10 mM) or PBS for 
24 hours prior to infection with different inocula of S. aureus. NAM 
treatment of human neutrophils resulted in elevated protein lev-
els of C/EBPε (Figure 3A, left). Associated with this change, NAM 
treatment reduced the survival of the pathogen in whole blood 
by 100 to 1,000 fold at 3 hours p.i. compared with that after PBS 
treatment (Figure 3A, right, and Supplemental Figure 5).
Notably, in our experiments, we used a NAM concentration of 
1 mM, which is similar to the plasma concentration previously 
measured in humans treated with NAM (47). Importantly, NAM 
had no direct antistaphylococcal activity when incubated in the 
absence of phagocytic cells (Figure 3B and Supplemental Figure 
6). As a further control, the NAM used in our study has been cell 
culture tested and was confirmed to be free of endotoxin (pyrogen) 
(Supplemental Figure 7).
To verify that the ex vivo effect of NAM is not related to altered 
viability of myeloid cells, we treated human blood with either 
NAM or PBS ex vivo and evaluated the survival of myeloid cell pop-
ulations after 24 hours by complete blood count (CBC) and trypan 
blue staining. Consistently, we showed no significant decrease in 
neutrophil viability after 24 hours of treatment with either PBS 
or NAM (Figure 3C and Supplemental Figures 8 and 9). Likewise 
at 24 hours, ex vivo NAM treatment had no significant impact on 
the viability of mononuclear cells compared with that of PBS treat-
ment (Figure 3C and Supplemental Figure 8).
Next, to determine the C/EBPε dependency of S. aureus killing, 
we isolated peripheral blood from WT and Cebpe–/– mice, pre-
treated the blood for 24 hours with either NAM (1 mM) or PBS 
(control), and then infected the blood with different inocula of 
S. aureus. Consistent with findings in human blood, in the WT 
groups, NAM pretreatment enhanced killing of S. aureus by more 
than 1,000 fold compared with that in PBS controls (Figure 3D 
and Supplemental Figure 10). By contrast, in Cebpe–/– groups, 
NAM pretreatment had no impact on the number of surviving   
S. aureus CFUs compared with that in PBS control groups (Fig-
ure 3D and Supplemental Figure 10). Pretreatment of WT murine 
peripheral blood with NAM for only 4 hours (instead of 24 hours) 
did not result in CFU differences (Supplemental Figure 11). Nota-
bly, the shown difference in the clearance of S. aureus by WT and 
Cebpe–/– blood was more modest in Figure 3D compared with that 
shown in Figure 1I. This could be attributed to differences in assay 
condition (standard whole blood assay versus gentamicin protec-
tion assay in whole blood): since C/EBPε-related granule proteins 
play a critical role in the killing of internalized bacteria, adjunctive 
killing of nonphagocytosed S. aureus by antibiotics, as shown in 
Figure 1I, could have accentuated the difference between WT and 
Cebpe–/– blood cell killing.
To test the critical role of C/EBPε in NAM-augmented killing 
in vivo, we injected WT and Cebpe–/– mice daily with either NAM 
(250 mg/kg) or PBS i.p., starting 24 hours prior to systemic (i.p.) 
infection with S. aureus. This dose has routinely and safely been 
used in other studies (48, 49). Strikingly, after 48 hours, WT mice 
treated with NAM showed approximately 100-fold lower S. aureus 
CFUs in the spleens and kidneys compared with that in PBS con-
trols (Figure 3E). In contrast to our findings in WT mice, NAM 
treatment had no impact on the number of bacterial CFUs recov-
ered from the spleens and kidneys of Cebpe–/– mice at 48 hours 
p.i. (Figure 3E). NAM treatment was also investigated against a 
strain of MRSA and enhanced clearance of the MRSA compared 
with PBS treatment (Supplemental Figure 12). These findings are 
consistent with the hypothesis that C/EBPε is important in the 
immunomodulatory activity of NAM.
NAM selectively enhances neutrophil killing of S. aureus. To determine 
the specific contribution of the myeloid cell lineages to S. aureus 
clearance in whole blood, we isolated neutrophil and mononuclear 
fractions from the blood of healthy human volunteers. We pre-
treated the cells with either PBS or NAM (1 mM) for 24 hours and 
then measured intracellular survival of S. aureus in each myeloid 
cell population using a standard gentamicin protection assay. We 
showed that NAM augmented killing of S. aureus by neutrophils 
(Figure 4A and Supplemental Figure 13) but not by monocytes 
(Figure 4B and Supplemental Figure 14). We also evaluated the 
impact of NAM on macrophage clearance of S. aureus. WT murine 
BMDMs showed improved killing of S. aureus after NAM treat-
ment (by less than 2 fold; Supplemental Figure 15), but the effect 
was much less dramatic than that observed with neutrophils.
Our ex vivo assays suggest that neutrophils are an important 
target of NAM antimicrobial activity. To investigate the critical 
role of neutrophils in vivo, we administered control or anti-PMN 
antibody to WT mice, as previously described above, and then 
measured S. aureus clearance either with or without NAM treat-
ment. We showed that, in the absence of neutrophils, NAM had no 
effect on the clearance of S. aureus (Figure 4C). It is notable that, in 
the absence of neutrophils, mice exhibited a higher S. aureus bur-
den that could potentially impact the effect of NAM on bacterial 
clearance. We repeated the experiment with a 10- to 20-fold lower 
inoculum and showed that NAM had no effect with the reduced 
bacterial load (Supplemental Figure 16).
Figure 1
Impaired response of Cebpe–/– mice to S. aureus infection. (A–E) WT 
and Cebpe–/– mice (n = 8 /group) were injected s.c. with S. aureus (left 
flank, ~2 × 107 CFUs; right flank, ~1 × 108 CFUs). (A) Overall body 
weight as percentage of original weight (mean ± SEM). P < 0.001. (B) 
Area of skin lesions (P < 0.001). Representative images of skin lesions 
on day 6 p.i. Arrows point to lesions from ~2 × 107 (left) and ~1 × 108 
(right) inocula. (C) CFUs from skin lesions, spleens, and kidneys on 
day 6 p.i. Dashed lines indicate limit of detection. (D) Neutrophil and 
macrophage counts from H&E-stained skin lesions 24 hours p.i. (E) 
CXCL1 and CXCL2 measured from skin lesions at 24 hours p.i. (n = 10 
lesions/group). (F) Survival of ~1.2 × 104 CFU/ml S. aureus in peripheral 
blood from WT and Cebpe–/– mice (n = 5/group). (G) Bacterial clear-
ance by BMDMs from WT and Cebpe–/– mice (n = 3/group). Data in 
D–G are mean ± SEM. (H) WT and Cebpe–/– mice (n = 6/group) were 
treated with anti-PMN antibodies or normal serum daily for 4 days and 
infected s.c. on day 2 with ~4 × 106 CFU S. aureus. CFUs recovered 
from skin lesions on day 4 p.i. (I) Intracellular survival assay using 
whole blood from WT and Cebpe–/– mice (n = 8/group). Representative 
histology (H&E) of infected skin lesions from WT and Cebpe–/– mice 
showing neutrophils with intracellular S. aureus (arrows). Scale bar: 
10 µM. Throughout, symbols indicate individual samples, and red bars 
indicate mean. *P < 0.05; **P < 0.01; ***P < 0.001.research article
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A previous report showed that administration of NAM to human 
volunteers can induce C/EBPα and C/EBPβ expression and granu-
locytosis (42). To determine whether an increased number of cir-
culating neutrophils explains, at least in part, the antimicrobial 
activity of NAM in our in vivo infection model, we administered 
either NAM (250 mg/kg) or PBS daily to mice and monitored their 
changes in myeloid cell populations over 3 days. We showed that 
under our study conditions, NAM treatment did not induce an 
increase in myeloid cell populations after 1, 2, or 3 days (Figure 4D 
and Supplemental Figure 17).
NAM induces expression of antimicrobial effectors downstream of   
C/EBPε. Because NAM killing of S. aureus appears to be C/EBPε 
dependent, we next investigated whether NAM activates the expres-
sion of antimicrobial effectors known to be downstream of C/EBPε.
Upon exposing human neutrophils to NAM (1 mM) for 6 to 12 
hours, we detected a 5-fold increase in the level of acetylation on 
core histone H3 at the promoter region of CEBPE (Figure 5A) and 
4-fold increase in acetylation of C/EBPε (Figure 5B and Supple-
mental Figure 18). This was accompanied by elevated protein lev-
els of C/EBPε and downstream antimicrobial targets CAMP and 
LTF (Figure 5C and Supplemental Figures 19 and 20). Treatment 
of WT murine neutrophils also induced protein expression of   
C/EBPε and LTF but not of CAMP (Figure 5D). By contrast, NAM 
treatment of Cebpe–/– murine neutrophils had no effect on the level 
of CAMP or LTF (Figure 5D), suggesting that NAM induction of 
LTF occurs through the activation of C/EBPε. We also probed for 
gp91phox (NOX2) expression and reactive oxygen species produc-
tion in neutrophils and found that NAM had no impact (Supple-
mental Figure 21).
We also investigated the effect of NAM on other myeloid cell 
lineages. We showed that NAM had no impact on C/EBPε, CAMP, 
and LTF expression in human monocytes (Figure 5E) but caused 
somewhat increased expression of C/EBPε and antimicrobial tar-
gets in macrophages (Supplemental Figures 22–24). The increased 
transcriptional activity of C/EBPε in macrophages was accompa-
nied by increased acetylation of histone H3 in the promoter region 
of CEBPE as well as increased protein acetylation (Supplemental 
Figures 22 and 23). In differentiated U937 myeloid cells stably 
transfected with pMTε, forced expression of C/EBPε directly pro-
moted increased levels of LTF and CAMP (Figure 5F).
In addition, we administered NAM systemically to noninfected 
WT mice (250 mg/kg/d, i.p.) and measured expression of Cebpe 
and downstream antimicrobial factors in murine bone marrow 
mononuclear cells. Expression analysis in these cells revealed 
increased levels of Cebpe, Camp, and Ltf mRNA and proteins after 
72 hours of NAM treatment (Supplemental Figures 25–27).
Prior studies have documented a role of Th17 cells in the clear-
ance of S. aureus (50). Therefore, we also evaluated whether T cells 
and murine protein of IL-17 and IFN-γ are impacted by treatment 
with NAM. As shown in Supplemental Figure 28, splenocytes taken 
from mice administered either NAM or PBS daily for 3 days, with or 
without S. aureus infection, did not secrete different levels of murine 
protein of IL-17a and IFN-γ following in vitro restimulations.
NAM augmented killing of S. aureus in vivo when given after the infec-
tious challenge. To evaluate whether NAM is beneficial for treatment 
of an existing infection, we established systemic infection in WT 
mice with S. aureus for 12 hours prior to commencing daily treat-
ment with NAM (Figure 6A). After 60 hours of infection, the num-
ber of bacteria recovered from the spleens and kidneys was 30- to 
1,000-fold lower in NAM-treated mice compared with that in PBS-
treated controls. These data indicate that NAM can be effective 
against S. aureus whether the compound is administered before or 
after infection is established.
In line with our data on S. aureus, we also showed that NAM pre-
treatment of human peripheral blood improved the outcome of 
infection with other important human pathogens, such as K. pneu-
moniae and P. aeruginosa (Figure 6B).
Taken together, our findings strongly suggest that increased 
expression of C/EBPε, induced by the epigenetic modulator 
NAM, can efficiently enhance the clearance of S. aureus both in 
vitro and in vivo.
Discussion
Steady advances in molecular medicine and genetics have helped 
broaden our understanding of the underlying pathophysiology 
of leukocyte disorders and provided a clearer representation of 
how cells and other factors of the immune system interact. In this 
study, we substantiated the clinical finding that patients with   
C/EBPε deficiency are highly prone to S. aureus infection. After   
S. aureus challenge, C/EBPε-deficient mice exhibited dramatic skin 
pathology, were unable to clear S. aureus at the infection site, and 
had permitted systemic spread of the bacteria to spleens and kid-
neys. The underlying defects of C/EBPε-deficient neutrophils are 
many and include the absence of critical antimicrobial factors such 
Figure 2
Induced overexpression of C/EBPε promotes killing of S. aureus in 
vitro. The promonocytic cell line U937 was stably transfected with 
either pMTε or vector control (pMT), differentiated using PMA, and 
treated with or without zinc (100 µM). The PMA-derived U937 cells 
were infected with S. aureus (Pig1) at multiple different MOI (bacte-
ria/macrophage) for 24 hours; data are mean ± SEM. Western blot 
revealed a 6.5-fold (6.5x) increase in C/EBPε protein expression in 
lysates from the infected zinc-treated cells carrying pMTε, compared 
with that of the controls.research article
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as LTF and cathelicidin (e.g., CAMP), which are likely to contribute 
to the dramatic infection phenotype. In vivo, increased numbers of 
these phagocytic cells not only failed to compensate for the severe 
functional defects, but paradoxically appeared to contribute to the 
severity of infection, since depletion of the defective neutrophils 
improved clearance of S. aureus and reduced the size of necrotic 
lesions. We showed that ineffective clearance of S. aureus by Cebpe–/– 
neutrophils permitted S. aureus to thrive within neutrophils and 
may further aggravate the infection. We, thereby, provide strong 
evidence that this transcription factor is essential for neutrophils, 
Figure 3
NAM augments killing of S. aureus by a C/EBPε-dependent mechanism. (A) Effect of NAM on clearance of S. aureus by human blood. Human blood 
(n = 4) was pretreated with NAM or PBS for 24 hours and inoculated with S. aureus (6.5 × 103 CFU/ml). The number to the right of the blot indicates 
fold change compared with ACTB. (B) NAM does not have direct antistaphylococcal activity. S. aureus (~104 CFU/ml) was treated with NAM or THB. 
(C) Effect of ex vivo NAM treatment on viability of human myeloid cells. Human blood (n = 5) was treated ex vivo with PBS or 1 mM NAM, and CBC 
was performed to determine the absolute (ABS) neutrophil and monocyte count for each volunteer at 0 and 24 hours. (D) Effect of NAM on clearance 
of S. aureus by murine blood. Blood from WT and Cebpe–/– mice (n = 6/group) was treated with NAM or PBS for 24 hours and then inoculated with   
S. aureus (~104 CFU/ml). Images show CFUs after 3 hours. (E) Effect of NAM on in vivo clearance of S. aureus. WT (n = 9) or Cebpe–/– mice (n = 7) 
were treated daily with NAM or PBS, beginning 24 hours prior to i.p. S. aureus (~107 CFUs) infection. CFU counts in WT and Cebpe–/– mice at 48 hours 
p.i. Dashed lines indicate limit of detection. One out of seven Cebpe–/– mice from each treatment group died and were excluded from analysis. (A, B, 
and D) Data are mean ± SEM. (C and D) Red bars indicate mean. Symbols indicate individual samples. *P < 0.05; **P < 0.01; ***P < 0.001.research article
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not only to avoid intracellular bacterial growth, but also to actively 
clear S. aureus, ensuring an effective innate immune system.
The profound phenotype of infected C/EBPε-deficient mice sug-
gests that this myeloid-specific factor controls a critical antimi-
crobial program tailored for killing of S. aureus. Preliminary data 
on K. pneumoniae and P. aeruginosa in human blood experiments 
suggest a similar mechanism playing a role in other pathogens as 
well. Low plasma levels of C/EBPε-regulated antimicrobials have 
been shown to be predictive of increased risk of death attributable 
to infection in humans (51). Based on the dramatic infection phe-
notype of the C/EBPε-deficient mice, we hypothesized and demon-
strated that enhanced transcriptional activity of C/EBPε in normal 
subjects, either by induced overexpression or by induction with 
NAM, could have a significant and often dramatic effect on killing 
of S. aureus both in vitro and in vivo. The absence of improved bac-
terial clearance in our C/EBPε-deficient models further underlines 
the interplay between C/EBPε and NAM.
HDAC inhibitors, such as NAM, influence transcriptional 
expression by controlling chromatin condensation and regulate 
proteins involved in acetylation (23–27). As a precursor to NAD+, 
NAM can block deacetylation and the regeneration of NAD+ 
through interception of an ADP-ribosyl-enzyme-acetyl peptide 
intermediate (29–31, 38, 52). NAD+-dependent transcriptional 
regulation was previously demonstrated for the highly conserved 
family members, C/EBPα and C/EBPβ (42). Moreover, transcrip-
tional activity mediated by C/EBPβ can be enhanced by increased 
acetylation of its lysine residues by the HDAC inhibitors NAM 
and trichostatin (28). In line with these findings, we suggest that 
NAM, in its role as an epigenetic modulator, can increase the pro-
tein expression of a select number of downstream targets mediated 
by C/EBPε, including the well-recognized antimicrobials CAMP 
and LTF (15, 19, 53). Among myeloid cell populations, neutrophils 
appear to be a particularly important target of NAM for the clear-
ance of S. aureus. Notably, and in contrast to human neutrophils, 
Figure 4
NAM selectively enhances neutrophil killing of   
S. aureus. (A) Effect of NAM on clearance of   
S. aureus by human neutrophils. Human neutro-
phils (n = 3 volunteers) were treated ex vivo with 
PBS or NAM (1 mM) for 20 hours and then infected 
with 2.4 × 108 CFU/ml preopsonized S. aureus in a 
gentamicin protection assay. Surviving intracellular 
bacteria recovered at indicated times (mean ± 
SEM) are shown. (B) Effect of NAM on clearance of   
S. aureus by human peripheral mononuclear cells. 
Human monocytes (n = 3 volunteers) were treat-
ed ex vivo with PBS or NAM (1 mM) for 20 hours 
and then infected with preopsonized S. aureus. 
Recovered intracellular bacteria (mean ± SEM) are 
shown. (C) Effect of NAM on in vivo clearance of 
S. aureus by WT mice depleted of neutrophils. WT 
mice (n = 6–9/group) were treated daily with NAM 
(250 mg/kg/d, i.p.) or with PBS beginning 24 hours 
prior to systemic (i.p.) infection with ~1 × 107 CFU   
S. aureus. Neutrophil depletion (or serum control) 
was performed in parallel. CFU count in spleens 
and kidneys of WT mice at 48 hours p.i. Dashed 
lines indicate limit of detection. (D) Effect of NAM 
treatment on granulocytosis in WT mice. WT mice 
(n = 5–12/group/time point) were treated with NAM 
(250 mg/kg/d, i.p.) or PBS, and CBC with auto-
mated differential was performed on blood taken at 
24, 48, and 72 hours to determine the population 
of neutrophils and monocytes. (C and D) Red bars 
indicate mean. Symbols indicate individual sam-
ples. *P < 0.05; **P < 0.01; ***P < 0.001.research article
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WT mouse neutrophils did not show increased CAMP expression 
when stimulated with NAM. This may reflect some difference 
between C/EBPε-mediated regulation of CAMP gene expression 
in humans and mice and is currently being investigated by our 
laboratories. We also probed for an additional antimicrobial target 
(NGAL) downstream of C/EBPε and found its expression was not 
affected by NAM in both human and mouse neutrophils (data not 
shown). Currently, we do not know which specific antimicrobial or 
antimicrobial combination downstream of C/EBPε is responsible 
for the clearance of S. aureus. However, since C/EBPε is known to 
be an essential regulator for the functional maturation of neutro-
phils, we speculate that C/EBPε may control a critical antimicro-
bial program that is inducible by NAM.
This program most likely controls specific elements of the neu-
trophil granules, which include a mixture of cytotoxic enzymes 
and peptides (e.g., LTF and CAMP), which bear not only a direct 
but also an indirect antibacterial effect by inducing the expression 
of cytokines and chemoattractants (54) as well as having a role 
in antigen presentation (55). It is notable that many neutrophil 
responses, including chemotaxis, exocytosis, respiratory burst 
activity, and chemokine synthesis, are mediated by p38MAPK, 
which is upstream and a direct activator of C/EBPε (56). Therefore, 
activation of upstream molecules regulating the activity of C/EBPε 
could be a further mechanism of how NAM exerts its antimicro-
bial effect. Dissecting the upstream and downstream components 
of the C/EBPε pathway will be an active area of future studies.
In our study of the myeloid cells, macrophages and monocytes, 
in comparison to neutrophils, appear to be more modestly 
impacted by C/EBPε deficiency or by NAM treatment for killing of  
S. aureus. Prior studies, however, have shown that C/EBPε-deficient 
macrophages have reduced expression of a number of immune-
related genes (e.g., Il18, Il10, mcp3, and Serpinb2) (16). We, therefore, 
speculate that C/EBPε expression in macrophages may still impact 
clearance of S. aureus indirectly through cytokine responses. How-
ever, neutrophils appear to have a critical role in C/EBPε-mediated 
responses to S. aureus. Future studies using hematopoietic recon-
stitution after myeloablative irradiation could directly address the 
central role of the transcription factor C/EBPε in hematopoietic 
cells as the critical mediator of S. aureus killing.
An important concern that arises from the study is whether the 
therapeutic effect documented with S. aureus could be achieved in 
human subjects using safe NAM doses. In human trials, NAM is 
frequently administered as a modifier to patients undergoing radio-
therapy (47, 48, 57, 58). In these trials, a plasma concentration of 
1 mM NAM is routinely achieved, a concentration that we used in 
our peripheral whole blood killing assays to demonstrate NAM effi-
cacy. Therefore, our data suggest that a NAM concentration safely 
achievable in humans could provide protection against S. aureus 
infection. The 250 mg/kg/d dosing in mice is a regimen that has 
been used safely in many murine studies (48, 49). That dose has not 
been widely tested in human subjects and is above the routine mega-
dose regimen used in clinical trials (80 mg/kg/d). However, stud-
Figure 5
NAM induces expression of antimicrobial effectors downstream of C/EBPε. (A) Effect of NAM on histone acetylation in human neutrophils. Blood 
was treated ex vivo with 1 mM NAM. Neutrophils were isolated, and ChIP was performed using an antibody against acetylated histone H3 (Ac-
H3) or IgG control. The samples were analyzed by PCR using primers specific for the CEBPE promoter region. Input chromatin was included as 
a positive control using primers for the ACTB gene. (B) Effect of NAM on acetylation of C/EBPε protein in human neutrophils. Neutrophils isolated 
from blood were treated with 1 mM NAM for 6 hours, and lysates were subjected to immunoprecipitation with an antibody against pan-acetylated 
lysine residues (acetyl-Lys), followed by Western blot (WB) with an antibody against C/EBPε. (C) Levels of C/EBPε, LTF, and CAMP in human 
neutrophils treated ex vivo with PBS or 1 mM NAM. (D) Levels of C/EBPε, LTF, and CAMP in neutrophils isolated from WT and Cebpe–/– mice   
(n = 15/genotype) treated ex vivo with PBS or 1 mM NAM for 20 hours. (E) Levels of C/EBPε, LTF, and CAMP in human monocytes treated ex vivo 
with PBS or 1 mM NAM for 20 hours. (F) Forced expression of C/EBPε directly promoted increased levels of LTF and CAMP. (A–F) Fold changes 
indicated were determined by densitometry (24 hours versus 0 hours). (A–C and E) Data represent 1 out of 3 human donors. For all instances, 
when human neutrophils or monocytes were used, blood from at least 3 human volunteers was used. Numbers to the right of blots indicate fold 
change compared with ACTB.research article
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ies have noted that the pharmacokinetics of NAM in humans and 
mice are quite different. In one report, an equivalent peak serum 
level was achieved with a dose of 80 to 90 mg/kg in humans and   
171 mg/kg in mice (48). Additionally, a review of NAM safety con-
cluded that though insufficient data are available to assess the upper 
level of safety in humans, with the newer preparations of NAM that 
are devoid of hepatotoxic contaminants, this is likely to be about   
350 mg/kg/d (59). Future studies will need to address the minimal 
safe NAM dose that induces clearance of S. aureus.
Also of clinical relevance, a previous study by Skokowa and col-
leagues showed that NAM treatment in humans at a dose of 10 to 
20 mg/kg/d induced neutrophilia in the blood of the patients at 
days 3 and 7 (42). The 250 mg/kg/d dosing in mice that achieved 
enhanced clearance of S. aureus did not induce additional clearance 
at days 1 to 3. However, given the recruitment of neutrophils with 
NAM administration in humans and the occasional association 
of excess neutrophils with immunopathology, human subjects 
receiving NAM for S. aureus infection would need to be monitored 
carefully for this side effect.
Our finding that NAM has an important effect on immune-
mediated killing of S. aureus in mouse and in human blood has a 
number of additional therapeutic implications. In an age when the 
number of antibiotics in the pipeline is limited and development 
of resistance occurs rapidly, use of complementary strategies to 
antibiotic treatment would provide a method of limiting develop-
ment of antibiotic resistance. Because C/EBPε is a transcriptional 
activator of a number of important antimicrobial factors, induc-
tion of resistance to multiple host factors is less likely. Likewise, 
the use of an immune boosting strategy coupled with convention-
al antibiotics could provide important synergy.
While the use of NAM against conventional bacteria has not been 
previously reported, the vitamin compound has shown promising 
efficacy in treatment of M. tuberculosis infection, based on human 
studies performed in the 1960s (43). Similarly, NAM administration 
is associated with a beneficial effect in patients with HIV infection 
(43). Immune response to HIV is hypothesized to cause vitamin B3 
deficiency, and the benefit of NAM supplementation comes from 
correction of this deficiency. In both cases, the role of C/EBPε in 
combating HIV and M. tuberculosis is unknown. Recently, Wurtele 
et al. reported that modulation of the yeast histone H3 Lys56 acety-
lation by NAM sensitized C. albicans to genotoxic and antifungal 
agents (44). We have demonstrated that NAM, as an HDAC inhibi-
tor, can improve host defense and thereby promote bacterial clear-
ance. NAM is not only effective against S. aureus, it also has dem-
onstrated efficacy against other major human pathogens, such as   
K. pneumoniae and P. aeruginosa, in our human peripheral blood kill-
ing assay. These findings reflect the broad potential of compounds 
with the ability to stimulate the activity of C/EBPε and related anti-
microbial targets. The effect of NAM and the associated contribu-
tion of C/EBPε and other downstream mediators in the treatment 
of pathogens are currently being explored by our laboratories.
In summary, we have demonstrated that C/EBPε is a regulatory 
factor that critically impacts the host’s ability to fight S. aureus 
infections. Manipulation of C/EBPε expression in neutrophils 
and monocytes/macrophages, either by forced overexpression or 
by pharmacologic application of NAM, leads to a clear therapeutic 
effect on S. aureus infection. Our results constitute a proof of prin-
ciple that compounds exerting modulatory effects of the myeloid-
specific transcription factor C/EBPε may be suitable candidates 
for antimicrobial therapeutics.
Methods
Mice. Cebpe–/– mice (12) and WT littermates were bred and maintained under 
pathogen-free conditions at an American Association for the Accreditation 
of Laboratory Animal Care–accredited animal facility at the Burns and Allen 
Research Institute at Cedars-Sinai Medical Center. Animals were housed in 
accordance with the procedures outlined in the Guide for the Care and Use 
of Laboratory Animals under an animal study proposal approved by the 
Cedars-Sinai Medical Center Institutional Animal Care and Use Committee. 
Cebpe–/– mice kept under the above mentioned conditions showed no signs of 
infection during life or at autopsy, with survivals equivalent to those of WT 
mice. Sex-matched mice used throughout our study were 6 to 10 weeks old.
Figure 6
NAM augmented killing of S. aureus in vivo when given after the infectious challenge. (A) Effect of NAM in WT mice already infected with S. aureus. 
Animals (n = 9/group) were systemically infected i.p. with ~2.0 × 107 CFU S. aureus and treated daily with either NAM (250 mg/kg/d, i.p.) or with 
PBS (control), beginning 12 hours p.i. The CFU count in spleens and kidneys of WT mice at 60 hours p.i. is shown. Dashed lines indicate limit of 
detection. Red bars indicate mean. Symbols indicate individual samples. (B) NAM enhances clearance of K. pneumoniae and P. aeruginosa from 
the blood of healthy human volunteers. Bacterial counts (mean ± SEM) recovered from the peripheral blood of human volunteers (n = 5) after the 
inoculation with 1.2 × 104 CFU/ml P. aeruginosa (left) or K. pneumoniae (right). *P < 0.05; **P < 0.01; ***P < 0.001.research article
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Bacterial strains and growth conditions. Unless otherwise indicated, WT   
S. aureus Pig1 (4), isolated from the skin of a child with atopic dermatitis, 
was used in the experiments. The MRSA clinical isolate COL (NRS100; 
NARSA) was also used.
S. aureus were propagated in Todd-Hewitt broth (THB; Difco) at 37°C, 
with shaking at 250 rpm, or on THB agar (THA). Overnight bacterial 
culture was diluted until an optical density at 600 nm, corresponding to 
approximately 108 CFU/ml, was reached. Bacteria were harvested by cen-
trifugation at 3,300 g for 10 minutes at 4°C and then washed twice with 
PBS (without Ca2+ and Mg2+; Mediatech). S. aureus strains were routinely 
cultured on Tryptic Soy sheep blood agar plates, and colonies with compa-
rable hemolysis phenotypes were selected for each experiment.
Murine skin infection model. S. aureus was pelleted, washed twice, and 
resuspended in PBS mixed 1:1 with sterile Cytodex beads (GE Health-
care), following an established protocol for generating localized S. aureus 
and S. pyogenes s.c. infection (4, 60). One hundred microliters of 2 sepa-
rate inocula, as specified (see the legend for Figure 1), were administered 
by s.c. injection into the respective 2 flanks of each mouse. Injections 
were performed with careful visualization of the needle to assure that 
they were not intramuscular. Serial dilutions were prepared and plated 
to confirm the actual inocula used.
Determination of lesion size and tissue bacterial CFUs. Baseline weights of 
mice were recorded prior to infection and daily thereafter until sacrifice. 
Lesions were measured with a caliper, daily throughout infection. Lesions 
were defined by darkened areas of dermonecrosis. Our method to mea-
sure lesion size has been previously reported (61). Briefly, skin lesions were 
quantified by multiplying the length and width of the lesion. Irregularly 
shaped lesions were broken down into smaller symmetrical pieces, and 
each piece was measured by the same method.
Following euthanization of mice, infected skin lesion tissue was asepti-
cally excised, thoroughly homogenized, and mixed in 1 ml PBS, as previ-
ously shown (61). Ten-fold serial dilutions of the homogenates were plated 
on THA for CFU determination. The spleen and both kidneys were asep-
tically removed from each animal and processed in the same way. When 
required, the appropriate homogenized suspensions (skin lesions) were 
centrifuged at 15,000 g for 10 minutes, and supernatants were stored at 
−80°C for subsequent analysis by ELISA.
Quantification of neutrophils and macrophages in infected skin lesions. WT and 
Cebpe–/– mice (n = 8 per group) were infected by s.c. injection of S. aureus at the 
specified inoculum (see the legend for Figure 1) and sacrificed at 24 hours 
p.i. Infected tissues (skin lesions) were then excised and fixed in 10% for-
malin (Medical Chemical Corporation) overnight. Paraffin embedding and 
H&E staining were performed by the Department of Pathology at Cedars-
Sinai Medical Center. Image acquisition was performed with the Zeiss Axio 
Imager M1 microscope and the AxioVision 4.6 software (Zeiss). A minimum 
of 3 mice (2 lesions per mouse) from each genotype were randomly selected 
for enumeration of macrophages and neutrophils. Two blinded observers 
counted the cells from 10 nonoverlapping high-power fields (original mag-
nification, ×400) within each lesion. The average count was obtained from 
each mouse in each group, and SEM was calculated from these averages.
ELISA. Mouse CXCL1-specific and CXCL2-specific ELISAs were per-
formed according to the manufacturer’s instructions (R&D Systems).
Isolation of murine bone marrow mononuclear cells and cultivation of 
BMDMs. Bone marrow cells were harvested from WT or Cebpe–/– mice. 
Bone marrow was flushed out of isolated femurs and tibiae with RPMI 
1640 medium and 10% heat-inactivated FBS using a 25-gauge needle. 
Cells were then incubated for 4 hours in a humidified atmosphere at 
37°C and 5% CO2 to deplete adherent cells. Nonadherent bone marrow 
cells were cultured with 10 ng/ml murine M-CSF (Peprotech) in RPMI 
1640 with 10% FBS for 7 days to induce BMDMs. Bone marrow mono-
nuclear cells were isolated from nondepleted bone marrow cells using 
Lymphocyte Separation Medium (Mediatech).
Intracellular survival assay (gentamicin protection assay) in macrophages. Macro-
phages were seeded at a density of 5 × 104 cells per well (100 µl) in 96-well tissue 
culture plates. Macrophages were infected with S. aureus at the specified MOI 
(see Figure 1G and Figure 2). To promote infection, bacteria were spun down 
onto the macrophages at 500 g for 10 minutes at room temperature, before 
incubating the cells in a humidified atmosphere at 37°C and 5% CO2. After 30 
minutes, macrophages were washed 3 times with prewarmed media to remove 
extracellular bacteria. Gentamicin (Invitrogen) was then added to each well at a 
final concentration of 400 µg/ml for 1.5 hours. At this time, the concentration 
of gentamicin in the media was reduced to 100 µg/ml for the remainder of the 
assay. At 24 hours p.i., cells were washed 3 times with PBS, then 100 µl of 0.02% 
Triton X-100 in water was added to each well and pipetted vigorously 10 times 
to promote macrophage lysis and release intracellular bacteria. Ten-fold serial 
dilutions of each cell lysate were immediately plated onto THA, and CFUs were 
enumerated following overnight incubation at 37°C. Data are representative 
of at least 2 independent experiments performed in triplicate.
For assays involving PMA-differentiated human U937 macrophages, 24 
hours prior to infection, media was replaced without G418 and PMA for 
the remainder of the time. Zinc (100 µM Zn2SO4) was added to the respec-
tive pMTε and control groups 24 hours prior to infection and was present 
for the remainder of the assay.
Neutrophil depletion in vivo. Depletion of neutrophils was carried out as 
described previously (62, 63). Briefly, mice were made neutropenic by i.p. 
administration of 150 µl rabbit anti-mouse PMN antibody (Cedarlane 
Labs) 24 hours prior (day –1) to s.c. infection with S. aureus on day 0 and 
every 24 hours thereafter, until sacrifice on day 4. The manufacturer certi-
fied that the antibody was sterile and suitable for use in cytotoxic assays 
and in vivo depletion. Control groups received equal amounts of normal 
rabbit serum (Sigma-Aldrich; sterile-filtered, cell culture and endotoxin 
tested) by i.p. injection.
WT and Cebpe–/– mice receiving either anti-mouse PMN antibody or nor-
mal serum (control) were infected s.c. with S. aureus on day 0 (refer to Murine 
skin infection model). Skin lesion areas were measured daily, and on day 4 (sac-
rifice) the CFUs in skin lesions, spleens, and kidneys were determined.
To confirm depletion of neutrophils after antibody injection, WT mice 
(n = 3/group) were sacrificed at day 0 and day 4 of infection. Splenocytes 
were collected after sacrifice and homogenized, and cells were stained with 
PE–anti-Ly6G monoclonal antibody and PE.Cy5–anti-CD11b monoclonal 
antibody (eBiosciences). The population of neutrophils (Ly6G+, CD11b+) 
were determined using a CyAnTM flow cytometer (Beckman Coulter), and 
the data were analyzed by Summit (Dako) software. The total population 
of neutrophils of mice treated with antibody was highly reduced on day 
0 (–72%) and day 4 (–96%; data not shown) compared with that of mice 
treated with normal serum.
Intracellular survival assay (gentamicin protection assay) in murine whole 
blood. Bacteria were pelleted, washed twice, diluted to 1.5 × 107 CFU/ml in   
50 µl PBS (without Ca2+ and Mg2+), and immediately mixed with 150 µl of 
freshly drawn murine (WT or Cebpe–/–; n = 8/group) peripheral whole blood 
in sterile heparinized 2-ml round-bottom Eppendorf tubes. Notably, blood 
from WT and Cebpe–/– mice contained approximately the same number of 
neutrophils per microliter (Supplemental Figure 4). Reactions were incu-
bated at 37°C on a rotary shaker.
After 15 minutes of infection, gentamicin (Invitrogen; working stock, 
5 mg/ml in PBS) was added to each 200 µl blood reaction at a final con-
centration of 400 µg/ml to kill extracellular bacteria. At 75 minutes p.i., 
the concentration of gentamicin in the blood was reduced to approxi-
mately 130 µg/ml for the remainder of the assay by adding 240 µl PBS 
to each blood reaction.research article
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Forty-microliter (35 and 60 minutes p.i.) or 120-µl (180 minutes p.i.) 
aliquots were taken from each blood reaction, diluted into 500 µl PBS (in 
sterile 0.6-ml Eppendorf tubes), and centrifuged at 15,000 g for 3 minutes 
at room temperature. After carefully removing the supernatant, pure water 
(200 µl) was added and pipetted vigorously 10 times to promote host cell 
lysis and release intracellular bacteria. Each 200-µl cell lysate was immedi-
ately plated onto THA using the spread-plate technique (30-ml agar plates 
to further dilute out any remaining gentamicin), and CFUs were enumer-
ated following overnight incubation at 37°C.
Development of U937-pMTε cells. As reported previously by our group 
(64), pMTε was constructed by inserting a full length of CEBPE cDNA at 
the XhoI and HindIII sites of the pMTCB6+ vector (pMT; gift from F.J. 
Rauscher III, The Wistar Institute, Philadelphia, Pennsylvania, USA). We 
used the human promonocytic U937 cell line (ATCC) stably transfected 
with pEGFP plasmid (Clontech Laboratories) and either zinc-inducible 
pMTε or control vector pMT. Cells were maintained at between 2 × 105 
cells/ml and 1 × 106 cells/ml in RPMI 1640 medium (Invitrogen) supple-
mented with 10% heat-inactivated FBS (Gemini Bio-Products), 2 mM 
l-glutamine, and G418 (neomycin, 900 µg/ml; Omega Scientific) for selec-
tion. Multiple polyclonal cultures (>98% GFP positive) were screened for 
zinc-inducible C/EBPε protein overexpression by Western blot analysis.
PMA-differentiated human U937 myeloid cells. U937 cells alone or carrying 
either pMTε or vector control were seeded at an appropriate density in tis-
sue culture plates. The cells were subsequently induced to differentiate by 
addition of 10 ng/ml PMA (Sigma-Aldrich) for 24 hours.
Human blood. Participants in our study included healthy humans with 
a negative history of infection, no antibiotic treatments, and no immune-
boosting supplements in the 4 weeks prior to donating blood. Peripheral 
blood was collected from individuals in a fasting condition. Blood was rou-
tinely collected in the presence of either heparin or K2 EDTA and was used 
immediately for downstream applications.
NAM. NAM (C6H6N2O; Fw 122.13), tested for cell culture and insect cell 
culture, was purchased from Sigma-Aldrich. On each occasion prior to use, 
NAM was prepared fresh in sterile endotoxin-free PBS (without Ca2+ and 
Mg2+) and sterilized through a nonpyrogenic 0.22-µm low-protein-binding 
filter (PALL Life Sciences). Each specific lot of NAM used in our study was 
confirmed to be endotoxin-free (pyrogen-free) using the end-point chro-
mogenic Limulus amebocyte lysate endochrome method (refer to Supple-
mental Methods and Supplemental Figure 7 for more detail).
Assessing the effect of NAM on the growth and viability of S. aureus. We assessed 
whether NAM, at the concentrations used in our study, adversely affect the 
growth and viability of S. aureus. PBS was chosen as an inert nongrowth 
medium, and THB was chosen as a suitable growth medium for S. aureus. 
Seventy-five microliters of NAM (1 mM and 10 mM final concentrations; 
in either THB or PBS) or THB or PBS alone (respective controls) were 
placed in sterile 2-ml round-bottom Eppendorf tubes and then inoculated 
with S. aureus (~1 × 104 CFU/ml in 25 µl of PBS or THB) and immediately 
briefly vortexed. Triplicate reactions were incubated at 37°C for 1, 3, and 6 
hours on a rotary shaker, at which time 10-fold serial dilutions were plated 
on THA for enumeration of CFUs.
In a different assay, S. aureus (~1 × 108 CFU/ml in THB) was incubated 
either with or without 50 mM NAM. Triplicate 1-ml reactions were incu-
bated at 37°C on a rotary shaker, and at various time points (6, 12, and 24 
hours), 10-fold serial dilutions were plated on THA for enumeration of 
CFUs. These assays were performed on 3 independent occasions.
Murine and human whole blood assays. This well-described phagocytic sur-
vival assay has been previously reported (4). Bacteria were pelleted, washed 
twice, diluted to the specified inoculum (see the legends for Figures 1, 3, 
and 6) in 25 µl PBS (without Ca2+ and Mg2+), and immediately mixed with 
75 µl of freshly drawn human or murine peripheral whole blood in sterile 
heparinized 2-ml round-bottom Eppendorf tubes. Reactions (performed 
in minimum in triplicate) were incubated at 37°C for 1 to 3 hours on a 
rotary shaker, at which time 10-fold serial dilutions were plated on THA 
for enumeration of surviving CFUs.
When required, freshly drawn human or murine peripheral blood was pre-
treated with NAM (1 mM or 10 mM) or PBS (without Ca2+ and Mg2+) prior to 
inoculation with bacteria. Pretreatment was performed in sterile, nontreated, 
low evaporation tissue culture plates (Becton Dickinson) for 24 hours in a 
humidified atmosphere (95% humidity) at 37°C and 5% CO2, with gentle 
mixing on a nutator. On each occasion, blood was aseptically taken from 
mice via cardiac puncture using a 22-gauge needle to minimize lysis and 
maintain the integrity of the blood for the duration of the respective assay.
Murine systemic infection. Mice were systemically infected by i.p. injection of 
~1 × 107 CFU/ml to 2 × 107 CFU/ml S. aureus for 48 hours. Following eutha-
nasia, the spleen and both kidneys were removed for CFU determination.
CBC of human and mouse blood specimens. CBCs were used to measure the 
viability of myeloid lineages in human and mouse blood. Blood specimens 
were collected in BD Microtainer tubes with K2 EDTA (Becton Dickinson). 
Specimens were analyzed for hematology testing within 3 hours of collec-
tion and were stored in racks or continuously mixed at room temperature 
during this time.
Human blood specimens were routinely analyzed by the Department of 
Pathology at Cedars-Sinai Medical Center. CBC with automated differen-
tial was performed using a Beckman Coulter LH 1500 Series Hematology 
Automation System.
Murine blood specimens were routinely analyzed by the Department of 
Comparative Medicine at Cedars-Sinai Medical Center. CBC with automated 
differential was performed using a Hemavet 950 FS Veterinary Hematology 
System (Drew Scientific Inc.). Automated functionality included wbc, rbc, 
Hb, HCT, MCV, MCH, MCHC, platelets, and 5-part wbc differential, includ-
ing neutrophils, lymphocytes, monocytes, eosinophils, and basophils.
Isolation of human neutrophils. Polymorphprep (Axis-Shield) was used for 
the isolation of neutrophils from human peripheral blood according to the 
manufacturer’s instructions.
Human neutrophils were maintained ex vivo in RPMI 1640 supplement-
ed with 10% heat-inactivated FBS and 2 mM l-glutamine in a humidified 
atmosphere at 37°C and 5% CO2. When indicated, immediately follow-
ing isolation, human neutrophils were treated ex vivo with either NAM (1 
mM) or PBS for 20 to 24 hours and subsequently used for Western blot or 
specific functional assays.
For some experiments, freshly drawn human peripheral blood was pre-
treated with either NAM (1 or 10 mM) or PBS (without Ca2+ and Mg2+), 
prior to isolating the neutrophils using Polymorphprep. Pretreatment of 
the human blood was performed in sterile, nontreated, low evaporation 
tissue culture plates (Becton Dickinson) for 20 to 24 hours in a humidi-
fied atmosphere (95% humidity) at 37°C and 5% CO2, with gentle mixing 
on a nutator.
Trypan blue exclusion, according to standard staining protocol, was 
used to measure the viability (over time) of neutrophils in culture or neu-
trophils isolated directly from blood.
Isolation of human monocytes. Human peripheral blood was collected in the 
presence of heparin and used immediately. Blood was layered over Lym-
phocyte Separation media (Fisher Scientific) according to manufacturer’s 
instructions and centrifuged at 1,000 g for 25 minutes at room tempera-
ture without the break engaged. The cell layer was isolated and washed 3 
times with RPMI 1640. Monocytes were isolated using Human Monocyte 
Isolation Kit II (Miltenyi Biotec) according to the manufacturer’s instruc-
tions. Briefly, the Monocyte Isolation Kit II is an indirect magnetic labeling 
system for the isolation of untouched monocytes from human peripheral 
blood mononuclear cells. Human monocytes were isolated by depletion of research article
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agar plates to further dilute out any remaining gentamicin), and CFUs 
were enumerated following overnight incubation at 37°C. A similar assay 
was performed using human monocytes.
ChIP. The ChIP Assay Kit (Upstate Biotechnology) was used, and chroma-
tin
 
was prepared for immunoprecipitation as instructed by the manufac-
turer. The sonicated chromatin
 
was immunoprecipitated with either 5 µg 
anti-acetylated histone H3 antibody or normal rabbit IgG antibody as nega-
tive control (Upstate Biotechnology). Immunoprecipitated DNA was sub-
sequently analyzed by PCR using primers specific for the CEBPE promoter 
region spanning the genomic region –797 to –518 base pairs upstream of 
the transcriptional start site (position: 21578530; Promoter ID 12948) that 
was localized by our group (10); input chromatin was analyzed for β-actin 
mRNA as a positive control. The optimal reaction conditions for PCR were 
determined for each primer pair. Primers were denatured at 95°C for 1 min-
ute and annealed at 60°C for 1 minute, followed by elongation at 72°C for 
1 minute; each product was amplified 35 cycles. PCR products were ana-
lyzed by 2.5% agarose/ethidium bromide gel electrophoresis. Densitometry 
of all agarose gels was performed using Quantity One software 4.6.3 (Bio-
Rad) to quantify fold changes. The primers used for ChIP analysis were as 
follows: human CEBPE, 5′-GCTTTGGCCAAGCCCAGGGA-3′ (forward), 
5′-TGCTGGGCTCCACCTACCCC-3′ (reverse); human ACTB, 5′-CTCCTC-
GGGAGCCACACGCA-3′ (forward), 5′-TAGGGGAGCTGGCTGGGTGG-3′ 
(reverse); murine Cebpe, 5′-TGAGGCTGCAGCTTGCCTGG-3′ (forward), 
5′-ACCAAGCTACCCCTGGCCCT-3′ (reverse); murine Actb, 5′-ACCTGT-
TACTTTGGGAGTGGCAAGC-3′ (forward), 5′-GTCGTCCCAGTTGGTA-
ACAATGCC-3′ (reverse).
Western blot and immunoprecipitation. Whole-cell extracts were produced 
by lysing cells (107) with 100 µl denaturing RIPA buffer (50 mM Tris HCl,   
pH 8; 150 mM NaCl; 1% NP-40; 0.5% sodium deoxycholate; 0.1% SDS) 
added with a protease inhibitor cocktail (Roche Molecular Biochemicals) 
on the day of extraction. Extracts were stored at –80°C until use.
For Western blot, protein lysates were boiled in Laemmli sample buf-
fer (Bio-Rad), resolved on 4% to 15% gradient SDS-PAGE gels, and trans-
ferred to nitrocellulose membranes (Sigma-Aldrich). Immunoblots were 
probed with anti-C/EBPε antibody (Santa Cruz Biotechnology Inc.), anti-
LTF antibody (Abcam), anti-CAMP antibody (Abcam), anti-gp91phox 
antibody (NOX2; Santa Cruz Biotechnology Inc.), and anti–lipocalin-2 
antibody (NGAL; R&D Systems) and developed using the enhanced che-
miluminescence kit (Pierce). ACTB (Sigma-Aldrich) was used as a control. 
Western blot data are representative of 1 out of 3 independently performed 
experiments. Densitometry of all blots was performed using Quantity One 
software 4.6.3 (Bio-Rad) to quantify fold changes.
We used an anti–acetyl-lysine antibody (ab21623; Abcam) for 
immunoprecipitation according to the manufacturer’s protocol. The input 
of the protein lysates was used as a loading control. 
Statistics. We used 2-tailed unpaired Student’s t test to compare 2 indepen-
dent groups when using ex vivo data; nonparametric Mann-Whitney U test 
was applied for the independent comparison of the murine in vivo CFU data. 
One-way ANOVA was used for the comparison of more than 2 independent 
groups, and 2-way ANOVA, in combination with Bonferroni as post-hoc test, 
was used to compare murine body weight or lesion size data sets obtained 
over time. Paired Student’s t test was used for the comparison of human 
blood samples treated with either NAM or PBS. We deemed a P value below 
0.05 as significant. GraphPad Prism was used for analyses.
Study approval. All animal experiments were approved by the Cedars-Sinai 
Medical Center Institutional Animal Care and Use Committee and per-
formed using accepted veterinary standards. Peripheral blood was obtained 
from healthy adult donors by the General Clinical Research Center at 
Cedars-Sinai Medical Center. All subjects provided written informed con-
sent. Experimentation using human blood were approved by the Cedars-
nonmonocytes (negative selection). Nonmonocytes were indirectly mag-
netically labeled with a cocktail of biotin-conjugated monoclonal antibod-
ies, as primary labeling reagent, and anti-biotin monoclonal antibodies 
conjugated to MicroBeads, as secondary labeling reagent.
Human monocytes were maintained ex vivo in RPMI 1640 supple-
mented with 10% FBS, 2 mM l-glutamine, and 50 ng/ml recombinant 
human M-CSF (PeproTech) in a humidified atmosphere at 37°C and 5% 
CO2. Human monocytes were treated ex vivo with either NAM (1 mM) 
or PBS for approximately 20 hours and subsequently used for Western 
blot or functional assays.
Isolation of mouse neutrophils. Isolation of neutrophils from murine whole 
blood was performed according to a protocol established by Cedarlane 
Labs. Blood was aseptically collected from mice via cardiac puncture using 
a 22-gauge needle to minimize lysis and maintain the integrity of the blood 
cells. Blood was collected in the presence of heparin and used immediately. 
rbc were pelleted by centrifugation at 1400 g for 10 minutes at room tem-
perature, without the brake engaged. The buffy coat (wbc layer) and the 
top layer of the rbc was harvested with a Pasteur pipette and transferred to 
a fresh tube. PBS (without Ca2+ and Mg2+) was added to wash and fully sus-
pend the cells, and the mixture was centrifuged (600 g, 10 minutes, room 
temperature) to re-pellet the cells. rbc were then lysed using standard pro-
tocol. wbc were subsequently resuspended in 4 ml of a serum-free medium 
(PBS without Ca2+ and Mg2+). 4 ml diluted wbc were then carefully layered 
over 3 ml Lympholyte-Mammal (Cedarlane Labs) at room temperature in 
a 15-ml centrifuge tube. The gradient was centrifuged at 800 g for 25 min-
utes at room temperature, without the brake engaged. The resulting inter-
facial band consisted of lymphocytes, and the pellet consisted of PMNs. 
Once the PMNs were obtained, further washing was carried out to remove 
any rbc membranes (rbc ghosts). The majority of the granulocytes were 
neutrophils (>70%).
Murine neutrophils were maintained ex vivo in RPMI 1640 supplement-
ed with 10% FBS and 2 mM l-glutamine and incubated in a humidified 
atmosphere at 37°C and 5% CO2. Murine neutrophils were treated ex vivo 
with either NAM (1 mM) or PBS for approximately 20 hours and subse-
quently used for Western blot.
Intracellular survival assay (gentamicin protection assay) in human neutrophils. 
S. aureus were opsonized with 10% prewarmed pooled human plasma and 
incubated for 20 minutes at 37°C under slow rotation. The preopsonized 
bacteria were pelleted, washed twice, diluted to the specified inoculum (see 
the legend for Figure 4) in 50 µl RPMI, and immediately mixed with 150 µl   
human neutrophils (6 × 105 total neutrophils) in sterile 2-ml round-
bottom Eppendorf tubes. Before being used in this assay, the neutrophils 
had been pretreated ex vivo with either NAM (1 mM) or PBS for 20 hours. 
Based on CBC data from at least 11 healthy human donors, a mean of 
4,000 neutrophils per microliter of human blood was assumed when deter-
mining an appropriate MOI to use in this assay. Reactions were incubated 
at 37°C on a rotary shaker.
After 20 minutes of infection, gentamicin (Invitrogen; working stock,   
5 mg/ml in RPMI) was added to each 200 µl neutrophil reaction at a final 
concentration of 400 µg/ml to kill extracellular bacteria. At 80 minutes p.i., 
the concentration of gentamicin in the reaction was reduced to approxi-
mately 130 µg/ml for the remainder of the assay by adding 240 µl RPMI to 
each neutrophil reaction.
Forty-microliter (55 and 80 minutes p.i.) or 120-µl (200 minutes p.i.) 
aliquots were taken from each neutrophil reaction, diluted into 500 µl 
RPMI (in a sterile 0.6-ml Eppendorf tube), and centrifuged at 15,000 g for 
3 minutes at room temperature. After carefully removing the supernatant, 
pure water (200 µl) was added and pipetted vigorously 10 times to promote 
host cell lysis and release intracellular bacteria. The entire 200-µl cell lysate 
was immediately plated onto THA using the spread-plate technique (30 ml  research article
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